B of A Securities Maintains Neutral on Cytokinetics, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Zemansky maintains a Neutral rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $70 to $60.
May 23, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities analyst Jason Zemansky maintains a Neutral rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $70 to $60.
The lowered price target from $70 to $60 by B of A Securities suggests a less optimistic outlook for Cytokinetics, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100